These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 27276713)
1. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052 [TBL] [Abstract][Full Text] [Related]
3. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004 [TBL] [Abstract][Full Text] [Related]
4. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669 [TBL] [Abstract][Full Text] [Related]
5. A systematic analysis with the hierarchical cluster analysis strategy on the complex interaction of TERT and CTNNB1 somatic mutations in Vietnamese hepatocellular carcinoma patients. Thu Nguyen T; Van Tran K; Cam Ho T; Xuan Nguyen H; Trong Nguyen T Gene; 2024 Nov; 927():148646. PubMed ID: 38851365 [TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078 [TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761 [TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. Li CL; Li CY; Lin YY; Ho MC; Chen DS; Chen PJ; Yeh SH Hepatology; 2019 Feb; 69(2):498-512. PubMed ID: 30070724 [TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368 [TBL] [Abstract][Full Text] [Related]
11. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. Cevik D; Yildiz G; Ozturk M World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106 [TBL] [Abstract][Full Text] [Related]
12. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Tornesello ML; Buonaguro L; Izzo F; Buonaguro FM Oncotarget; 2016 May; 7(18):25087-102. PubMed ID: 26943571 [TBL] [Abstract][Full Text] [Related]
13. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma. Kim YJ; Yoo JE; Jeon Y; Chong JU; Choi GH; Song DG; Jung SH; Oh BK; Park YN Int J Cancer; 2018 Dec; 143(12):3155-3168. PubMed ID: 29987895 [TBL] [Abstract][Full Text] [Related]
15. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747 [TBL] [Abstract][Full Text] [Related]
16. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868 [TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114 [TBL] [Abstract][Full Text] [Related]
18. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Ko E; Seo HW; Jung ES; Kim BH; Jung G Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952 [TBL] [Abstract][Full Text] [Related]
19. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Hsu HC; Jeng YM; Mao TL; Chu JS; Lai PL; Peng SY Am J Pathol; 2000 Sep; 157(3):763-70. PubMed ID: 10980116 [TBL] [Abstract][Full Text] [Related]
20. The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study. Matsuzaki Y; Sato M; Saito Y; Karube M; Doy M; Shoda J; Abei M; Tanaka N; Hadama T; Kinoshita M J Exp Clin Cancer Res; 1999 Sep; 18(3):379-89. PubMed ID: 10606185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]